TD Asset Management
VYNE icon

TD Asset Management’s VYNE Therapeutics VYNE Stock Holding History

TD Asset Management’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-429
Closed -$143K – 1447
2019
Q4 		$143K Buy
429
+21
+5% +$7K ﹤0.01% 1376
2019
Q3 		$132K Sell
408
-3
-0.7% -$968 ﹤0.01% 1317
2019
Q2 		$177K Buy
411
+11
+3% +$5.44K ﹤0.01% 1304
2019
Q1 		$226K Buy
400
+8
+2% +$3.84K ﹤0.01% 1300
2018
Q4 		$116K Hold
392
– – ﹤0.01% 1375
2018
Q3 		$278K Buy
+392
New +$242K ﹤0.01% 1375

Other funds holding VYNE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TD Asset Management's VYNE Position: Q1 2020 in Review

TD Asset Management sold out of VYNE Therapeutics (VYNE) in Q1 2020, closing a stake of 429 shares — an estimated $143K sold.

TD Asset Management first reported a position in VYNE in Q3 2018 and held it in 6 quarters. The position peaked at $278K in Q3 2018. 93 funds tracked by Wall St. Rank hold VYNE as of Q1 2020.

  • TD Asset Management reported no remaining VYNE Therapeutics position as of Q1 2020 after selling out during the quarter.
  • TD Asset Management sold 429 VYNE Therapeutics shares in Q1 2020, an estimated $143K.
  • TD Asset Management first reported a position in VYNE Therapeutics in Q3 2018 and held it in 6 quarters.
  • TD Asset Management's VYNE Therapeutics position peaked at $278K in Q3 2018.
  • 93 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2020.

Based on TD Asset Management's 13F filing for Q1 2020, filed 15 May 2020.